About This Show
For 50 years, Drug and Therapeutics Bulletin (DTB) has provided rigorous and independent evaluations of, and practical advice on, individual treatments and the overall management of disease for doctors, pharmacists and other healthcare professionals.
DTB has always been wholly independent of the pharmaceutical industry, Government and regulatory authorities. DTB is also free of advertising and other forms of commercial sponsorship.Read more »
Most Recent Episode
July 2018: managing herbal-drug interactions
In July’s podcast, James Cave (DTB Editor-in-Chief) and David Phizackerley (DTB Deputy Editor) discuss the risk of drug interactions with herbal medicines.
Read the editorial: https://dtb.bmj.com/content/56/7/73.
The editors also review the evidence for ocrelizumab for relapsing MS and early primary progressive MS (https://dtb.bmj.com/content/56/7/80), and discuss the role of metformin in people with type 1 diabetes (https://dtb.bmj.com/content/56/7/78).Read more »